Identification

Name
Carprofen
Accession Number
DB00821  (APRD00849)
Type
Small Molecule
Groups
Approved, Vet Approved, Withdrawn
Description

Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. It is no longer marketed for human usage, after being withdrawn on commercial grounds. [Wikipedia]

Structure
Thumb
Synonyms
  • (+-)-6-chloro-alpha-Methylcarbazole-2-acetic acid
  • (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid
  • 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid
  • 6-chloro-alpha-Methyl-9H-carbazole-2-acetic acid
  • Carprofen
  • Carprofène
  • Carprofeno
  • Carprofenum
External IDs
C 5720 / C 8012 / Ro 20-5720/000
International/Other Brands
lmadyl (Roche) / lmafen (Roche) / Rimadyt (Roche)
Categories
UNII
FFL0D546HO
CAS number
53716-49-7
Weight
Average: 273.714
Monoisotopic: 273.05565634
Chemical Formula
C15H12ClNO2
InChI Key
PUXBGTOOZJQSKH-UHFFFAOYSA-N
InChI
InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
IUPAC Name
2-(6-chloro-9H-carbazol-2-yl)propanoic acid
SMILES
CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1

Pharmacology

Indication

For use as a pain reliever in the treatment of joint pain and post-surgical pain.

Structured Indications
Not Available
Pharmacodynamics

Carprofen is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen. It is no longer used in the clinical setting, but is approved for use in dogs. Carprofen is non-narcotic and has characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models.

Mechanism of action

The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. In an in vitro study using canine cell cultures, carprofen demonstrated selective inhibition of COX-2 versus COX-1.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Rapidly and nearly completely absorbed (more than 90% bioavailable) when administered orally.

Volume of distribution
Not Available
Protein binding

High (99%)

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

Approximately 8 hours (range 4.5–9.8 hours) in dogs.

Clearance
Not Available
Toxicity

Symptoms of NSAID overdose include dizziness and nystagmus. Oral LD50 in mouse and rat is 282 mg/kg and 149 mg/kg, respectively.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Carprofen Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Carprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Carprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Carprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabCarprofen may increase the anticoagulant activities of Abciximab.Approved
AcebutololCarprofen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Carprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Carprofen is combined with Acemetacin.Approved
AcenocoumarolCarprofen may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinCarprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Carprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Carprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Carprofen is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Alendronic acid.Approved
AliskirenCarprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Alminoprofen.Experimental
AlprenololCarprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Carprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Carprofen is combined with Amcinonide.Approved
AmikacinCarprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideCarprofen may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinCarprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodCarprofen may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Carprofen is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Carprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Carprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Carprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Carprofen is combined with Anisodamine.Investigational
annamycinCarprofen may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Carprofen is combined with Antipyrine.Approved
Antithrombin III humanCarprofen may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanCarprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Carprofen is combined with Apocynin.Investigational
ApramycinCarprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Carprofen is combined with Apremilast.Approved, Investigational
ArbekacinCarprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinCarprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanCarprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololCarprofen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Carprofen is combined with Atamestane.Investigational
AtenololCarprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Carprofen is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Carprofen.Approved
BalsalazideCarprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminCarprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Carprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCarprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinCarprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Carprofen.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Carprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Carprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Carprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Carprofen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Carprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololCarprofen may decrease the antihypertensive activities of Betaxolol.Approved
BevantololCarprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Carprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Carprofen.Approved, Investigational
BisoprololCarprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinCarprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololCarprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Carprofen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Carprofen is combined with Bucillamine.Investigational
BucindololCarprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Carprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Carprofen is combined with Bufexamac.Experimental
BufuralolCarprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Bumadizone.Experimental
BumetanideCarprofen may decrease the diuretic activities of Bumetanide.Approved
BupranololCarprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Carprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Carprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Carprofen.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Carprofen.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Carprofen.Approved
CarteololCarprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCarprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Carprofen is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Carprofen.Approved, Investigational
CeliprololCarprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinCarprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Carprofen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Carprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Carprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Carprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Carprofen.Approved
CinoxacinCarprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidCarprofen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Carprofen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Carprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Carprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Carprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Carprofen.Vet Approved
CloranololCarprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Carprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Carprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Carprofen is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Carprofen is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Carprofen.Experimental
CyclosporineCarprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Carprofen is combined with D-Limonene.Investigational
Dabigatran etexilateCarprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinCarprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCarprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanCarprofen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinCarprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Carprofen is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Carprofen.Experimental
DesirudinCarprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Carprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Carprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Carprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Carprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Carprofen.Approved, Investigational
DextranCarprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Carprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Carprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Carprofen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinCarprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Carprofen.Approved, Vet Approved
DicoumarolCarprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Carprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Carprofen is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Carprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Carprofen.Approved
DihydrostreptomycinCarprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Carprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Carprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Carprofen.Approved
DoxorubicinCarprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneCarprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Carprofen is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Carprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Carprofen is combined with E-6201.Investigational
Edetic AcidCarprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCarprofen may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Carprofen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Carprofen.Approved
EnoxacinCarprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinCarprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Carprofen.Experimental
EpanololCarprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Carprofen is combined with Epirizole.Approved
EpirubicinCarprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneCarprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Carprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Carprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Carprofen is combined with Equilin.Approved
EsmololCarprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Carprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Carprofen is combined with Estrone sulfate.Approved
Etacrynic acidCarprofen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Carprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Carprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateCarprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Carprofen.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Carprofen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Carprofen is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Carprofen is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Carprofen is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Carprofen is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Carprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Carprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Carprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Feprazone.Experimental
Ferulic acidCarprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Carprofen.Approved, Investigational
FleroxacinCarprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Carprofen.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Carprofen is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Fludrocortisone.Approved
FluindioneCarprofen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineCarprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Carprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Carprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Carprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Carprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Carprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Carprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxCarprofen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumCarprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Carprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Carprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carprofen.Approved
FramycetinCarprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideCarprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateCarprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinCarprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinCarprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Carprofen.Approved, Withdrawn
GemifloxacinCarprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCarprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinCarprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACarprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Carprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinCarprofen may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Carprofen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Carprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Carprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Carprofen is combined with HE3286.Investigational
HeparinCarprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Carprofen is combined with Higenamine.Investigational
HydralazineCarprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Carprofen.Approved, Investigational
Hygromycin BCarprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Carprofen is combined with Icatibant.Approved
IdarubicinCarprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxCarprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Carprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Carprofen.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Carprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Carprofen.Approved
IndenololCarprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Carprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Carprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Indoprofen.Withdrawn
INNO-206Carprofen may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carprofen.Approved, Investigational
IsepamicinCarprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Carprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Carprofen is combined with Istaroxime.Investigational
KanamycinCarprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Carprofen.Approved
LabetalolCarprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololCarprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Carprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Carprofen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Carprofen is combined with Leflunomide.Approved, Investigational
LepirudinCarprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanCarprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololCarprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCarprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Carprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Carprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Carprofen.Approved
LonazolacThe risk or severity of adverse effects can be increased when Carprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Carprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Carprofen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Carprofen is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Carprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Carprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Carprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Carprofen is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Carprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Carprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Carprofen.Approved
MelagatranCarprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Carprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Carprofen.Approved, Vet Approved
MepindololCarprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineCarprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Carprofen is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Carprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololCarprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen.Approved
MetoprololCarprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideCarprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinCarprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Carprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Carprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Carprofen.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Carprofen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Carprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Carprofen.Approved
NadololCarprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCarprofen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatCarprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Carprofen.Approved
Nalidixic AcidCarprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Carprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Carprofen is combined with NCX 1022.Investigational
NeamineCarprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololCarprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinCarprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinCarprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Carprofen.Approved
NetilmicinCarprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Carprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Carprofen is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Carprofen is combined with Nitroaspirin.Investigational
NorfloxacinCarprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Carprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carprofen.Approved
OlsalazineCarprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Carprofen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Carprofen.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Carprofen is combined with Orgotein.Vet Approved
OtamixabanCarprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxaprozin.Approved
Oxolinic acidCarprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololCarprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Carprofen is combined with Parecoxib.Approved
ParomomycinCarprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Carprofen is combined with Parthenolide.Investigational
PazufloxacinCarprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCarprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCarprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateCarprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateCarprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Carprofen.Approved
PhenindioneCarprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCarprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Carprofen.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carprofen.Approved, Investigational
PindololCarprofen may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidCarprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinCarprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideCarprofen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Pirfenidone.Approved, Investigational
Piromidic acidCarprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Carprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pirprofen.Experimental
Platelet Activating FactorCarprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinCarprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinCarprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Carprofen.Approved
Porfimer sodiumCarprofen may increase the photosensitizing activities of Porfimer sodium.Approved, Investigational
PractololCarprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Carprofen.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Carprofen is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Carprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Carprofen can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Carprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Carprofen is combined with Propacetamol.Approved, Investigational
PropranololCarprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Carprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Carprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Carprofen.Vet Approved
Protein CCarprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanCarprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCarprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinCarprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Carprofen is combined with PTC299.Investigational
PuromycinCarprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Carprofen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Carprofen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Carprofen.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Carprofen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinCarprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinCarprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Risedronate.Approved, Investigational
RivaroxabanCarprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Carprofen.Investigational, Withdrawn
RosoxacinCarprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinCarprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinCarprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Carprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Carprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Carprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Carprofen.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Carprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Carprofen is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Carprofen is combined with Serrapeptase.Investigational
SisomicinCarprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinCarprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Carprofen.Approved
SotalolCarprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CCarprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinCarprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinCarprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Carprofen.Approved
SpironolactoneCarprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Carprofen is combined with SRT501.Investigational
StreptomycinCarprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinCarprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carprofen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Carprofen.Approved
SulodexideCarprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Carprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Suxibuzone.Experimental
TacrolimusCarprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Carprofen.Approved
TalinololCarprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Carprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Carprofen is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Carprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carprofen.Approved, Investigational
TemafloxacinCarprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Carprofen.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Carprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Carprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Carprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Carprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Carprofen is combined with Teriflunomide.Approved
TertatololCarprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololCarprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Carprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Carprofen is combined with Tixocortol.Approved
TobramycinCarprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Carprofen is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Carprofen.Approved
TorasemideCarprofen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Carprofen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Carprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Carprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneCarprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Carprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Carprofen is combined with Triptolide.Investigational
TrovafloxacinCarprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinCarprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Carprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Carprofen.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Carprofen.Investigational, Withdrawn
ValrubicinCarprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Carprofen.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Carprofen.Approved
VerteporfinCarprofen may increase the photosensitizing activities of Verteporfin.Approved, Investigational
WarfarinCarprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCarprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Carprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Carprofen.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Carprofen is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinCarprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinCarprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Berger, L. and Corraz, A.J.; US. Patent 3,896,145; July 22,1975; assigned to Hoffmann- LaRoche, Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB14959
KEGG Compound
C18364
PubChem Compound
2581
PubChem Substance
46505357
ChemSpider
2483
BindingDB
50097346
ChEBI
364453
ChEMBL
CHEMBL1316
Therapeutic Targets Database
DAP000975
PharmGKB
PA164781361
Wikipedia
Carprofen
MSDS
Download (24.5 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
Packagers
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)195-199Berger, L. and Corraz, A.J.; US. Patent 3,896,145; July 22,1975; assigned to Hoffmann- LaRoche, Inc.
water solubilityPractically insoluble at 25 °CNot Available
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00379 mg/mLALOGPS
logP4.09ALOGPS
logP3.88ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)4.42ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area53.09 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity74.16 m3·mol-1ChemAxon
Polarizability28.56 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9742
Caco-2 permeable+0.5595
P-glycoprotein substrateNon-substrate0.7062
P-glycoprotein inhibitor INon-inhibitor0.985
P-glycoprotein inhibitor IINon-inhibitor0.9319
Renal organic cation transporterNon-inhibitor0.8485
CYP450 2C9 substrateNon-substrate0.7405
CYP450 2D6 substrateNon-substrate0.8318
CYP450 3A4 substrateNon-substrate0.6389
CYP450 1A2 substrateInhibitor0.6573
CYP450 2C9 inhibitorNon-inhibitor0.7193
CYP450 2D6 inhibitorNon-inhibitor0.9481
CYP450 2C19 inhibitorNon-inhibitor0.7037
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.794
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8521
BiodegradationNot ready biodegradable0.9874
Rat acute toxicity3.4155 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9725
hERG inhibition (predictor II)Non-inhibitor0.8697
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-2910000000-d2961d6d33669b09ac4d

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Carbazoles
Direct Parent
Carbazoles
Alternative Parents
Indoles / Benzenoids / Aryl chlorides / Pyrroles / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 4 more
Substituents
Carbazole / Indole / Aryl chloride / Aryl halide / Benzenoid / Pyrrole / Heteroaromatic compound / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, carbazoles (CHEBI:364453)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10. [PubMed:10895904]
  2. Brideau C, Van Staden C, Chan CC: In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res. 2001 Nov;62(11):1755-60. [PubMed:11703020]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
  4. Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. [PubMed:15939622]
  5. Narlawar R, Perez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K: Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91. [PubMed:17181139]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. [PubMed:15939622]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:43